Chemistry: molecular biology and microbiology – Vector – per se
Reexamination Certificate
2006-06-06
2006-06-06
Kerr, Kathleen M. (Department: 1656)
Chemistry: molecular biology and microbiology
Vector, per se
C435S069100, C435S325000, C424S236100, C424S239100, C536S023700, C530S350000, C514S002600, C514S012200
Reexamination Certificate
active
07056729
ABSTRACT:
Agents for treating pain, methods for producing the agents and methods for treating pain by administration to a patient of a therapeutically effective amount of the agent. The agent can include a clostridial neurotoxin, or a component or fragment or derivative thereof, attached to a targeting moiety, wherein the targeting moiety is selected from a group consisting of transmission compounds which can be released from neurons upon the transmission of pain signals by the neurons, and compounds substantially similar to the transmission compounds.
REFERENCES:
patent: 4189426 (1980-02-01), Li
patent: 4481139 (1984-11-01), Folkers et al.
patent: 4664911 (1987-05-01), Uhr et al.
patent: 4719231 (1988-01-01), Umezawa et al.
patent: 5410019 (1995-04-01), Coy et al.
patent: 5538733 (1996-07-01), Emery et al.
patent: 5714468 (1998-02-01), Binder
patent: 5744131 (1998-04-01), Edwards et al.
patent: 5766605 (1998-06-01), Sanders et al.
patent: 5846216 (1998-12-01), Gonzales et al.
patent: 5853695 (1998-12-01), Srivastava et al.
patent: 5861284 (1999-01-01), Nishimura et al.
patent: 5891842 (1999-04-01), Kream
patent: 5955368 (1999-09-01), Johnson et al.
patent: 5965406 (1999-10-01), Murphy
patent: 5989545 (1999-11-01), Foster et al.
patent: 6632440 (2003-10-01), Quinn et al.
patent: 95/32738 (1995-07-01), None
patent: 96/33273 (1996-10-01), None
patent: 98/01754 (1998-01-01), None
patent: 98/07864 (1998-02-01), None
patent: 99/17806 (1999-04-01), None
XP001011356, Berge, O-G et al., “Selective Neurotoxic Lesions of Descending Serotonergic and Noradrenergic Pathways in the Rat”; Journal of Neurochemistry; 44(4):1156-1161 (1985).
XP001012206, Benoliel, R et al., “Actions of intrathecal diphtheria toxin-substance P fusion protein on models of persistent pain”; Pain; 79(2-3):243-253 (1999).
XP001011386, Garzon, J et al., “Effect of intrathecal injection of pertusis toxin on substance P norepinephrine and serotonin contents in various neural structures of arthritic rats”; Life Sciences; 47(21):1915-1924 (1990).
XP-000869767, Intracellular Messengers Contributing to Persistent Nociception and Hyperalgesia Induced by L-Glutamate and Substance P in the Rat Formalin Pain Model, Terence J. Coderre, and Kiran Yashpal, European Journal of Neuroscience, vol. 6, pp. 1328-1334, 1994.
XP-002091075, Histochemical localization of galactose-containing glycoconjugates in sensory neurons and their processes in the central and peripheral nervous system of the rat, Wolfgang J. Streit, et al., The Journal of Histochemistry and Cytochemistry, vol. 33, No. 10, p.p 1042-1052, 1985.
XP-000857076, Mosaic Structures of Neurotoxins Produced from Clostridium botulinum types C and D organisms, Morlishi et al., Biochimica et Biophysica Acta, 1307 (1996) 123-126.
Morre et al., Lancet 349 1746 (1997).
Ueda, “In Vivo Molecular Signal Transduction . . . ” Jpn J Pharmacol. vol. 79, 1999, pp 263-8 (Abstract).
Nichols et al, “Transmission of Chronic Nociception . . . ” Science, vol. 286, Nov. 1999, pp. 1558-1561.
Lopes & Couture, “Localization of Bradykinin-Like . . . ” Neuroscience, vol. 78, 1997, pp. 481-497.
Vigna et al, “Characterization of Antibodies . . . ” J Neurosci, vol. 14, 1994, pp. 834-845.
Principles of Neural Science Third Edition, Edited by Kandel et al (one page).
Babenko et al, “Experimental Human Muscle Pain . . . ” Pain, vol. 82, 1999, pp. 1-8.
Garrison & Rall, “Autacoids; Drug Therapy of Inflammation”.
Henry, “Substance P and Inflammatory . . . ” Disease Therapy, 1993.
Tsuda et al “In Vivo Pathway . . . ” BR J Pharmacol, vol. 127, 1999, pp 449-56.
Welch et al, “Sensitivity of Embryonic Rat . . . ” Toxicon, vol. 38, 2000, pp 245-58.
Mathias et al, “Topical Casaicin for Chronic Neck Pain . . . ” Abstract, American Journal of Physical Medicine & Rehabilitation, vol. 74, 1995, pp. 39-44.
Furst, “Transmitters Involved in Antinociception in the Spinal Cord” Abstract, Brain Research Bulletin, vol. 48, 1999, pp 129-141.
Populain et al., Inhibition of Transmitter Release by Botulinum Neurotoxin A Eur.J.Biochem, vol. 185, 1989, pp. 197-203.
Van Hagen et al, “Neuropeptides and Their Receptors” Ann Med, vol. 31 Suppl2, pp. 15-22.
Allergan Inc.
German Joel B.
Kam Chih-Min
Kerr Kathleen M.
Stathakis Dean G.
LandOfFree
Botulinum neurotoxin-substance P conjugate or fusion protein... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Botulinum neurotoxin-substance P conjugate or fusion protein..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Botulinum neurotoxin-substance P conjugate or fusion protein... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3676078